Matthew MacEwan is the founder, president and chief scientific officer of Retectix, LLC, located in St. Louis. Retectix is a medical device company focused on the development and production of nanofabricated surgical meshes and biomaterials using novel platform technology developed at Washington University in St. Louis. In his leadership role at Retectix, MacEwan is responsible for product development, pre-clinical/clinical testing, regulatory compliance and corporate strategy. MacEwan is a member of the Medical Scientist Training Program at Washington University in St. Louis and is pursuing a Ph.D. in biomedical engineering and an M.D. with clinical specialization in neurosurgery. Before attending Washington University in St. Louis, MacEwan graduated summa cum laude with a bachelor’s degree in biomedical engineering from Case Western Reserve University in Cleveland, Ohio, with a specialization in polymer biomaterials/biomaterial biocompatibility.